Altimmune (ALT) Gains from Sales and Divestitures (2017 - 2025)
Altimmune (ALT) reported Gains from Sales and Divestitures of $286653.0 for Q4 2025, down 0.8% year-over-year from $288977.0 in Q4 2024, and up 7.0% quarter-over-quarter from $267903.0 in Q3 2025.
Altimmune (ALT) Gains from Sales and Divestitures (2017 - 2025) Analysis & Trends
Altimmune (ALT) has 9 years of Gains from Sales and Divestitures data on file, last reported at $286653.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $286653.0, down 0.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $286653.0 (down 0.8% YoY), and the FY2025 annual result was $286653.0, down 0.8% from the prior year.
- Gains from Sales and Divestitures grew to $286653.0 in Q4 2025 per ALT's latest filing, from $267903.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $288977.0 in Q4 2024 and troughed at $4687.0 in Q4 2021.
- A 5-year average of $158523.7 and a median of $107830.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2021 and 2022: Gains from Sales and Divestitures tumbled 95.72% in 2021, then soared 1478.84% in 2022.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $4687.0 in 2021, then soared by 1478.84% to $74000.0 in 2022, then surged by 55.43% to $115018.0 in 2023, then jumped by 151.25% to $288977.0 in 2024, then retreated by 0.8% to $286653.0 in 2025.
- Business Quant data shows ALT's Gains from Sales and Divestitures at $286653.0 in Q4 2025, $267903.0 in Q3 2025, and $288977.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 286,653.00 |
| Dec 31, 2025 | 286,653.00 |
| Sep 30, 2025 | 267,903.00 |
| Sep 30, 2025 | 267,903.00 |
| Dec 31, 2024 | 288,977.00 |
| Dec 31, 2024 | 288,977.00 |
| Sep 30, 2024 | 288,040.00 |
| Sep 30, 2024 | 288,040.00 |
| Jun 30, 2024 | 286,165.00 |
| Jun 30, 2024 | 286,165.00 |
| Dec 31, 2023 | 115,018.00 |
| Dec 31, 2023 | 115,018.00 |
| Sep 30, 2023 | 100,642.00 |
| Sep 30, 2023 | 100,642.00 |
| Jun 30, 2023 | 98,768.00 |
| Jun 30, 2023 | 98,768.00 |
| Dec 31, 2022 | 74,000.00 |
| Dec 31, 2022 | 74,000.00 |
| Sep 30, 2022 | 46,653.00 |
| Sep 30, 2022 | 46,653.00 |